These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38561039)

  • 1. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma.
    Gong R; Wang J; Xing Y; Wang J; Chen X; Lei K; Yu Q; Zhao C; Li S; Zhang Y; Wang H; Ren H
    Cancer Lett; 2024 May; 590():216838. PubMed ID: 38561039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3
    Wang X; Lang M; Zhao T; Feng X; Zheng C; Huang C; Hao J; Dong J; Luo L; Li X; Lan C; Yu W; Yu M; Yang S; Ren H
    Oncogene; 2017 May; 36(21):3048-3058. PubMed ID: 27991933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
    Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
    Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.
    Wang L; Gu F; Liu CY; Wang RJ; Li J; Xu JY
    Tumour Biol; 2013 Apr; 34(2):853-8. PubMed ID: 23242609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
    Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
    BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SKA3 Expression as a Prognostic Factor for Patients with Pancreatic Adenocarcinoma.
    Buchholz K; Durślewicz J; Klimaszewska-Wiśniewska A; Wiśniewska M; Słupski M; Grzanka D
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
    Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
    Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
    Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
    Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas.
    Luo X; Yang Z; Liu X; Liu Z; Miao X; Li D; Zou Q; Yuan Y
    Tumour Biol; 2017 May; 39(5):1010428317699129. PubMed ID: 28466777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma.
    Venkat S; Tisdale AA; Schwarz JR; Alahmari AA; Maurer HC; Olive KP; Eng KH; Feigin ME
    Genome Res; 2020 Mar; 30(3):347-360. PubMed ID: 32029502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Masugi Y; Yamazaki K; Emoto K; Effendi K; Tsujikawa H; Kitago M; Itano O; Kitagawa Y; Sakamoto M
    Lab Invest; 2015 Mar; 95(3):308-19. PubMed ID: 25599535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gli1 expression in pancreatic ductal adenocarcinoma and its clinical significance.
    Abula Y; Yi C; Wang XY; Wang M; Qin RY; Guo YQ; Lin H; Li HJ
    Genet Mol Res; 2015 Oct; 14(4):12323-9. PubMed ID: 26505381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
    Iakovlev V; Siegel ER; Tsao MS; Haun RS
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
    Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
    Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of AGR2 in pancreatic ductal adenocarcinoma.
    Riener MO; Pilarsky C; Gerhardt J; Grützmann R; Fritzsche FR; Bahra M; Weichert W; Kristiansen G
    Histol Histopathol; 2009 Sep; 24(9):1121-8. PubMed ID: 19609859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
    Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
    Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.